NxStage Medical (NASDAQ:NXTM) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

A number of other analysts have also issued reports on the stock. Zacks Investment Research lowered shares of NxStage Medical from a “hold” rating to a “sell” rating in a research report on Saturday, August 11th. ValuEngine lowered shares of NxStage Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, August 7th. One analyst has rated the stock with a sell rating and four have given a hold rating to the company. The company has a consensus rating of “Hold” and an average price target of $30.00.

NASDAQ NXTM opened at $28.32 on Tuesday. The company has a market capitalization of $1.86 billion, a PE ratio of -128.73 and a beta of -0.04. NxStage Medical has a 52-week low of $22.70 and a 52-week high of $28.75.

A number of large investors have recently added to or reduced their stakes in NXTM. BlackRock Inc. increased its holdings in NxStage Medical by 10.5% in the second quarter. BlackRock Inc. now owns 5,289,606 shares of the medical device company’s stock worth $147,581,000 after buying an additional 501,922 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in NxStage Medical in the second quarter worth approximately $11,424,000. Water Island Capital LLC increased its holdings in NxStage Medical by 47.3% in the first quarter. Water Island Capital LLC now owns 1,184,707 shares of the medical device company’s stock worth $29,452,000 after buying an additional 380,561 shares during the last quarter. LMR Partners LLP acquired a new position in NxStage Medical in the second quarter worth approximately $7,438,000. Finally, Elo Mutual Pension Insurance Co acquired a new position in NxStage Medical in the first quarter worth approximately $6,116,000. Hedge funds and other institutional investors own 83.23% of the company’s stock.

About NxStage Medical

NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.

See Also: New Google Finance Tool and Screening Stocks

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.